The Comparative Cost-Effectiveness of Cabozantinib, Everolimus and Axitinib in Advanced Renal Cell Carcinoma (ARCC) After Failure of Prior Therapy- Scottish Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.242
https://www.valueinhealthjournal.com/article/S1098-3015(17)30576-4/fulltext
Title :
The Comparative Cost-Effectiveness of Cabozantinib, Everolimus and Axitinib in Advanced Renal Cell Carcinoma (ARCC) After Failure of Prior Therapy- Scottish Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30576-4&doi=10.1016/j.jval.2017.08.242
First page :
A440
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
220